I
InMed Pharmaceuticals Inc.
INMCIK 0001728328NasdaqEmerging GrowthPharmaceutical PreparationsA1CAFY ends Jun 30
Period
FY 2025
Revenue
$4.94M
Net Income
$-8.20M
Total Assets
$15.58M
Equity
$13.43M
Shares Out
3.31M
Op. Cash Flow
$-7.77M
Business
InMed Pharmaceuticals Inc. is a pharmaceutical company developing proprietary small‑molecule drug candidates that act as preferential signaling ligands of CB1 and CB2 receptors and other targets linked to human disease. It offers pharmaceutical product candidates (notably INM‑901 for Alzheimer’s, INM‑089 for dry AMD, and INM‑755 cream for epidermolysis bullosa) and commercial rare, non‑intoxicating cannabinoid ingredients via its BayMedica subsidiary. Its business comprises drug discovery/development programs and a B2B manufacturing/commercial segment for cannabinoid products. It distributes primarily to pharmaceutical partners, health and wellness manufacturers and B2B distributors across North America, Europe and other international markets.
Summary from filing dated 2025-09-23
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Sales | 5 | 5 | 4 | 1 | — | |
| Cost of sales | 3 | 3 | 3 | 545,889 | — | |
| Gross profit | 2 | 1 | 1 | 543,546 | — | |
| Research and development | 3 | 3 | 4 | 7 | 5 | |
| General and administrative | 7 | 6 | 6 | 7 | 4 | |
| Amortization and depreciation | 212,839 | 219,600 | 202,249 | 185,657 | 120,866 | |
| Foreign Exchange Loss | 28,471 | 61,921 | — | −117,551 | −163,101 | |
| Total operating expenses | 10 | 9 | 10 | 18 | 10 | |
| Interest and other income | 155,882 | 527,901 | 492,440 | 96,090 | 16,017 | |
| Finance expense | −371,549 | — | — | — | — | |
| Loss before income tax expense | −8 | −8 | −8 | −19 | — | |
| Income tax expense | — | −7,100 | −13,100 | — | — | |
| Net loss for the year | −8 | −8 | −8 | −19 | −10 | |
| Basic (in Dollars per share) | −8.36 | −20.14 | −3.25 | −33.17 | −37.96 | |
| Diluted (in Dollars per share) | −8.36 | −20.14 | −3.25 | −33.17 | −37.96 | |
| Basic (in Shares) | 975,985 | 381,053 | 2 | 560,829 | — | |
| Diluted (in Shares) | 975,985 | 381,053 | 2 | 560,829 | 268,793 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 11 | 7 | 9 | 6 | 7 | |
| Short-term investments | 43,384 | 43,064 | 44,422 | 44,804 | 46,462 | |
| Accounts receivable (less provision for credit losses of $2,424 and $nil as of June 30, 2025 and 2024, respectively) | 465,104 | 352,838 | 260,399 | 88,027 | 11,919 | |
| Inventories, net | 961,173 | 1 | 2 | 2 | — | |
| Prepaids and other current assets | 321,747 | 477,749 | 498,033 | 797,225 | 956,762 | |
| Total current assets | 13 | 9 | 11 | 10 | 8 | |
| Property, equipment and ROU assets, net | 992,199 | 1 | 723,426 | — | 326,595 | |
| Intangible assets, net | 2 | 2 | 2 | 2 | 1 | |
| Other assets | 100,000 | 100,000 | 104,908 | 176,637 | 14,655 | |
| Total Assets | 16 | 12 | 14 | 13 | 10 | |
| Accounts payable and accrued liabilities | 1 | 2 | 2 | 2 | 2 | |
| Current portion of lease obligations | 435,507 | 317,797 | 375,713 | 404,276 | 80,483 | |
| Total current liabilities | 2 | 2 | 2 | 3 | 2 | |
| Lease obligations, net of current portion | 305,755 | 644,865 | 15,994 | 389,498 | 189,288 | |
| Total Liabilities | 2 | 3 | 2 | 4 | 2 | |
| Commitments and Contingencies (Note 12) | — | — | — | — | — | |
| Common shares, no par value, unlimited authorized shares: 2,002,186 and 445,908 as of June 30, 2025 and 2024, respectively, issued and outstanding | 91 | 83 | 78 | 71 | 61 | |
| Additional paid-in capital | 39 | 35 | 36 | — | — | |
| Accumulated deficit | −117 | −109 | −101 | −93 | −75 | |
| Accumulated other comprehensive income | 128,569 | 128,569 | 128,569 | 128,569 | 128,569 | |
| Total Shareholders Equity | 13 | 9 | 12 | 9 | 7 | |
| Total Liabilities and Shareholders Equity | 16 | 12 | 14 | 13 | 10 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Amortization and depreciation | 212,839 | 219,600 | 202,249 | 185,657 | 120,866 | |
| Share-based compensation | 119,307 | 137,714 | 278,155 | — | — | |
| Amortization of right-of-use assets | 321,885 | 384,918 | 393,748 | 326,133 | — | |
| Interest income received on short-term investments | −34 | −1,250 | — | — | — | |
| Unrealized foreign exchange loss | 75,928 | 12,262 | 1,183 | 1,770 | — | |
| Inventory write-down | — | 305,812 | 308,937 | — | — | |
| Credit losses | 2,424 | — | 46,775 | — | — | |
| Inventories | 283,151 | 66,220 | 565,561 | −2 | — | |
| Prepaids and other currents assets | 173,980 | 20,284 | 299,192 | 190,661 | −823,172 | |
| Other non-current assets | — | 4,908 | 5,507 | −61,432 | −14,161 | |
| Accounts receivable | −114,690 | −92,439 | −219,147 | −40,008 | 40,198 | |
| Accounts payable and accrued liabilities | −249,728 | 45,282 | −806,530 | −811,599 | 346,685 | |
| Deferred rent | — | −16,171 | — | — | — | |
| Lease obligations | −429,880 | −397,422 | −426,575 | — | — | |
| Total cash used in operating activities | −8 | −7 | −7 | −16 | −10 | |
| Purchase of property and equipment | — | −9,293 | −160,014 | −39,108 | −1,725 | |
| Sale of short-term investments | 42,270 | 42,082 | 42,268 | — | — | |
| Purchase of short-term investments | −42,270 | −42,082 | −42,268 | — | — | |
| Total cash used in investing activities | — | −9,293 | −661,804 | −672,999 | −1,725 | |
| Proceeds from the exercise of pre-funded warrants | — | 175 | 646 | — | — | |
| Proceeds from the private placement | 8 | 5 | 11 | — | — | |
| Proceeds from the sale of pre-funded warrants | 5 | — | — | — | — | |
| Share issuance costs | −883,978 | −562,151 | — | — | — | |
| Total cash provided by financing activities | 12 | 5 | 11 | 15 | 11 | |
| Increase (decrease) in cash and cash equivalents during the year | 5 | −2 | — | — | — | |
| Income taxes | — | 7,100 | 13,100 | — | — | |
| Interest | — | — | — | — | — | |
| Preferred investment options to its placement agent | 281,810 | 325,699 | 691,484 | 192,491 | — | |
| Fair value of warrant modification recorded as equity issuance costs | 116,482 | 4 | — | — | — | |
| Recognition of Right-of-use asset and corresponding operating lease | 187,223 | 968,376 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is InMed Pharmaceuticals Inc.'s CIK number?
InMed Pharmaceuticals Inc.'s SEC CIK number is 0001728328 (1728328). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find InMed Pharmaceuticals Inc.'s SEC filings?
All of InMed Pharmaceuticals Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.